The Lancet

Claire M Rickard,Nicole M Marsh,Emily N Larsen,Matthew R McGrail,Nicholas Graves,Naomi Runnegar,Joan Webster,Amanda Corley,David McMillan,John R Gowardman,Debbie A Long,John F Fraser,Fenella J Gill,Jeanine Young,Marghie Murgo,Evan Alexandrou,Md Abu Choudhury,Raymond J Chan,Nicole C Gavin,Azlina Daud,Annamaria Palermo,Adrian Regli,E Geoffrey Playford

doi : 10.1016/S0140-6736(21)00351-2

ARTICLES| VOLUME 397, ISSUE 10283, P1447-1458, APRIL 17, 2021

The optimal duration of infusion set use to prevent life-threatening catheter-related bloodstream infection (CRBSI) is unclear. We aimed to compare the effectiveness and costs of 7-day (intervention) versus 4-day (control) infusion set replacement to prevent CRBSI in patients with central venous access devices (tunnelled cuffed, non-tunnelled, peripherally inserted, and totally implanted) and peripheral arterial catheters.

خرید پکیج و مشاهده آنلاین مقاله

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Victoria Jane Hall,Sarah Foulkes,Andre Charlett,Ana Atti,Edward J M Monk,Ruth Simmons,Edgar Wellington,Michelle J Cole,Ayoub Saei,Blanche Oguti,Katie Munro,Sarah Wallace,Peter D Kirwan,Madhumita Shrotri,Amoolya Vusirikala,Sakib Rokadiya,Meaghan Kall,Maria Zambon,Mary Ramsay,Tim Brooks,Colin S Brown,Meera A Chand,Susan Hopkinsand the SIREN Study Group

doi : 10.1016/S0140-6736(21)00675-9

ARTICLES| VOLUME 397, ISSUE 10283, P1459-1469, APRIL 17, 2021

Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to investigate whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection.

خرید پکیج و مشاهده آنلاین مقاله

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

Mattia Galli,Stefano Benenati,Davide Capodanno,Francesco Franchi,Fabiana Rollini,Domenico D'Amario,Italo Porto,Dominick J Angiolillo

doi : 10.1016/S0140-6736(21)00533-X

ARTICLES| VOLUME 397, ISSUE 10283, P1470-1483, APRIL 17, 2021

Whether guided selection of antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) is effective in improving outcomes compared with standard antiplatelet therapy remains controversial. We assessed the safety and efficacy of guided versus standard selection of antiplatelet therapy in patients undergoing PCI.

خرید پکیج و مشاهده آنلاین مقاله

Radiation pneumonitis and chemotherapy in a patient with multiple myeloma

Pierre Cuchet,Xavier Valette

doi : 10.1016/S0140-6736(21)00315-9

CLINICAL PICTURE| VOLUME 397, ISSUE 10283, P1484, APRIL 17, 2021

خرید پکیج و مشاهده آنلاین مقاله

Migraine: epidemiology and systems of care

Messoud Ashina,Zaza Katsarava,Thien Phu Do,Dawn C Buse,Patricia Pozo-Rosich,Aynur ?zge,Abouch V Krymchantowski,Elena R Lebedeva,Krishnamurthy Ravishankar,Shengyuan Yu,Simona Sacco,Sait Ashina,Samaira Younis,Timothy J Steiner,Richard B Lipton

doi : 10.1016/S0140-6736(20)32160-7

SERIES|MIGRAINE| VOLUME 397, ISSUE 10283, P1485-1495, APRIL 17, 2021

Migraine is a neurovascular disorder that affects over 1 billion people worldwide. Its widespread prevalence, and associated disability, have a range of negative and substantial effects not only on those immediately affected but also on their families, colleagues, employers, and society. To reduce this global burden, concerted efforts are needed to implement and improve migraine care that is supported by informed health-care policies. In this Series paper, we summarise the data on migraine epidemiology, including estimates of its very considerable burden on the global economy. First, we present the challenges that continue to obstruct provision of adequate care worldwide. Second, we outline the advantages of integrated and coordinated systems of care, in which primary and specialist care complement and support each other; the use of comprehensive referral and linkage protocols should enable continuity of care between these systems levels. Finally, we describe challenges in low and middle-income countries, including countries with poor public health education, inadequate access to medication, and insufficient formal education and training of health-care professionals resulting in misdiagnosis, mismanagement, and wastage of resources.

خرید پکیج و مشاهده آنلاین مقاله

Migraine: disease characterisation, biomarkers, and precision medicine

Messoud Ashina,Gisela M Terwindt,Mohammad Al-Mahdi Al-Karagholi,Irene de Boer,Mi Ji Lee,Debbie L Hay,Laura H Schulte,Nouchine Hadjikhani,Alexandra J Sinclair,H?kan Ashina,Todd J Schwedt,Peter J Goadsby

doi : 10.1016/S0140-6736(20)32162-0

SERIES|MIGRAINE| VOLUME 397, ISSUE 10283, P1496-1504, APRIL 17, 2021

Migraine is a disabling neurological disorder, diagnosis of which is based on clinical criteria. A shortcoming of these criteria is that they do not fully capture the heterogeneity of migraine, including the underlying genetic and neurobiological factors. This complexity has generated momentum for biomarker research to improve disease characterisation and identify novel drug targets. In this Series paper, we present the progress that has been made in the search for biomarkers of migraine within genetics, provocation modelling, biochemistry, and neuroimaging research. Additionally, we outline challenges and future directions for each biomarker modality. We also discuss the advances made in combining and integrating data from multiple biomarker modalities. These efforts contribute to developing precision medicine that can be applied to future patients with migraine.

خرید پکیج و مشاهده آنلاین مقاله

Migraine: integrated approaches to clinical management and emerging treatments

Messoud Ashina,Dawn C Buse,H?kan Ashina,Patricia Pozo-Rosich,Mario F P Peres,Mi Ji Lee,Gisela M Terwindt,Rashmi Halker Singh,Cristina Tassorelli,Thien Phu Do,Dimos D Mitsikostas,David W Dodick

doi : 10.1016/S0140-6736(20)32342-4

SERIES|MIGRAINE| VOLUME 397, ISSUE 10283, P1505-1518, APRIL 17, 2021

Migraine is a highly disabling neurological disorder that directly affects more than 1 billion individuals worldwide. Available treatment options differ between countries and include acute, preventive, and non-pharmacological therapies. Because of major progress in the understanding of migraine pathogenesis, novel mechanism-based medications have emerged and expanded the armamentarium of treatments. We provide a comprehensive overview of the current standard of care that will enable informed clinical management. First, we discuss the efficacy, tolerability, and safety profile of various pharmacological therapies for acute and preventive treatment of migraine. Second, we review the current knowledge on non-pharmacological therapies, such as neuromodulation and biobehavioural approaches, which can be used for a multidisciplinary approach to clinical management. Third, we emphasise that any effective treatment strategy starts with building a therapeutic plan tailored to individual clinical characteristics, preferences, and needs. Finally, we explore the outlook of emerging mechanism-based treatments that could address unmet challenges in clinical management of migraine.

خرید پکیج و مشاهده آنلاین مقاله